SINO BIOPHARM(HK:01177) Ge Long Hui·2026-01-15 05:32Group 1 - The core viewpoint of the article is that China Biopharmaceutical has announced the acquisition of private biotech company Hygieia, which specializes in small interfering RNA (siRNA) drugs, with a maximum base consideration of 1.2 billion yuan [1] - This acquisition will enable China Biopharmaceutical to establish a new generation of cardiovascular innovation pipeline and strengthen its presence in weight management and metabolic disease sectors, while also expanding into the chronic disease management market [1] - The report suggests that this acquisition enhances China Biopharmaceutical's innovation capabilities and licensing potential, further solidifying its position as a leader among Chinese innovative pharmaceutical companies [1] Group 2 - The target price for China Biopharmaceutical is set at 10.8 Hong Kong dollars, with a "buy" rating assigned [1]